Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders

Annals of Neurology

Volumn 49, Issue 5, 2001, Pages 561-574

  Tarnopolsky, Mark A ^a,c   Beal, M Flint ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ASCORBIC ACID; CARNITINE; CARNITINE ACYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE; CARRIER PROTEIN; CREATINE; CREATINE KINASE; CREATINE PHOSPHATE; DICHLOROACETIC ACID; GINKGO BILOBA EXTRACT; GLYCINE AMIDINOTRANSFERASE; IDEBENONE; LACTIC ACID; LEVACECARNINE; LIPID; MITOCHONDRIAL DNA; NICOTINAMIDE; NITRIC OXIDE; ORNITHINE; OXOGLUTARATE DEHYDROGENASE; PEROXYNITRITE; PYRUVATE DEHYDROGENASE; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; RIBOFLAVIN; RILUZOLE; THIOCTIC ACID; UBIDECARENONE; UNINDEXED DRUG;

ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG SAFETY; ENERGY METABOLISM; HUMAN; LACTIC ACIDOSIS; MITOCHONDRION; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; CREATINE; ENERGY METABOLISM; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 0035002174     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.1028     Document Type: Article

References (193)

1. Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997; 41:646-653.
2. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999;9:147-163.
3. Beal MF. Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol 1996;6:661-666.
4. Simon DK, Standaert DG. Neuroprotective therapies. Med Clin North Am 1999;83:509-523, viii.
5. Bogdanov MB, Ramos LE, Xu X , Beal MF. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 1998;71:1321-1324.
6. O'Gorman E, Piendl T, Muller M, et al. Mitochondrial intermembrane inclusion bodies: the common denominator between human mitochondrial myopathies and creatine depletion, due to impairment of cellular energetics. Mol Cell Biochem 1997;174:283-289.
7. Pitkanen S, Robinson BH. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest 1996;98: 345-351.
8. Simon DK, Johns DR. Mitochondrial disorders: clinical and genetic features. Annu Rev Med 1999;50:111-127.
9. Peng TI, Jou MJ, Sheu SS, Greenamyre JT. Visualization of NMDA receptor-induced mitochondrial calcium accumulation in striatal neurons. Exp Neurol 1998;149:1-12.
10. 2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell 1997;89:93-103.
11. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-1312.
12. Mecocci P, MacGarvey U, Kaufman AE, et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 1993;34:609-616.
13. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-751.
14. Raha S, Robinson BH. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci 2000;25:502-508.
15. Robinson BH. Human cytochrome oxidase deficiency. Pediatr Res 2000;48:581-585.
16. Bensimon G, Lacomblez L, Meininger V, Group ARS. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
17. Matthews RT, Yang L, Jenkins BG, et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998;18:156-163.
18. Brewer GJ , Wallimann TW. Protective effect of the energy precursor creatine against toxicity of glutamate and b-amyloid in rat hippocampal neurons. J Neurochem 2000;74:1968-1978.
19. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-4397.
20. Klivenyi P, Ferranre RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.
21. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999;157:142-149.
22. Pulido SM, Passaquin AC, Leijendekker WJ, et al. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett 1998;439:357-362.
23. Stadhouders AM, Jap PH, Winkler HP, et al. Mitochondrial creatine kinase: a major constituent of pathological inclusions seen in mitochondrial myopathies. Proc Natl Acad Sci USA 1994;91:5089-5093.
24. Tarnopolsky MA, Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 1999;22:1228-1233.
25. Sullivan PG, Geiger JD, Martson MP, Scheff SW. Dietary supplement creatine protects against traumatic brain injury. Ann Neurol 2000;48:723-729.
26. Klopstock T, Schlamp V, Schmidt F, et al. Creatine monohydrate in mitochondrial diseases: a double-blind, placebo-controlled, cross-over study in 16 patients with chronic progressive external opthalmolegia or mitochondrial myopathy. Neurology 1999;52:A543-A544.
27. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997;20:1502-1509.
28. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52:854-857.
29. Vorgerd M, Grehl T, Jager M, et al. Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial [see comments]. Arch Neurol 2000; 57:956-963.
30. Walter MC, Lochmuller H, Reilich P, et al. Creatine monohydrate in muscular dystrophies: a double-blind, placebo-controlled clinical study. Neurology 2000;54:1848-1850.
31. Tarnopolsky MA. Potential benefits of creatine monohydrate supplementation in the elderly. Curr Opin Clin Nutr 2000;3: 497-502.
32. Juhn MS, Tarnopolsky M. Oral creatine supplementation and athletic performance: a critical review. Clin J Sport Med 1998; 8:286-297.
33. Guthmiller P, Van Pilsum JF, Boen JR, McGuire DM. Cloning and sequencing of rat kidney L-arginine:glycine amidinotransferase: studies on the mechanism of regulation by growth hormone and creatine. J Biol Chem 1994;269:17556-17560.
34. Stockler S, Hanefeld F. Guanidinoacetate methyltransferase deficiency: a newly recognized inborn error of creatine biosynthesis. Wien Klin Wochenschr 1997;109:86-88.
35. van der Knaap MS, Verhoeven NM, Maaswinkel-Mooij P, et al. Mental retardation and behavioral problems as presenting signs of a creatine synthesis defect. Ann Neurol 2000;47:540-543.
36. Leuzzi V, Bianchi MC, Tosetti M, et al. Brain creatine depletion: guanidinoacetate methyltransferase deficiency (improving with creatine supplementation). Neurology 2000;55: 1407-1410.
37. Stockler S, Hanefeld F, Frahn J. Creatine replacement therapy in quanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 1996;348:789-790.
38. Sora I, Richman J, Santoro G, et al. The cloning and expression of a human creatine transporter. Biochem Biophys Res Commun 1994;204:419-427.
39. Steenge GR, Lambourne J, Casey A, et al. Stimulatory effect of insulin on creatine accumulation in human skeletal muscle. Am J Physiol 1998;275:E974-E979.
40. Loike JD, Zalutsky DL, Kaback E, et al. Extracellular creatine regulates creatine transport in rat and human muscle cell. Proc Natl Acad Sci USA 1988;85:807-811.
41. Guerrero-Ontiveros ML, Wallimann T. Creatine supplementation in health and disease: effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol Cell Biochem 1998;184:427-437.
42. Parise G, Parshad A, Wallimann T, Tarnopolsky MA. The effect of creatine mtCK and CreaT protein expression following resistance training. Can J Appl Physiol 2000;25:396.
43. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41:160-165.
44. Lodi R, Schapira AH, Manners D, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000;48: 72-76.
45. Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia, Proc Natl Acad Sci USA 1999;96:11492-11495.
46. Matthews PM, Allaire C, Shoubridge EA, et al. In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 1991;41:114-120.
47. Forsberg AM, Nilsson E, Werneman J, et al. Muscle composition in relation to age and sex. Clin Sci (Colch) 1991;81: 249-256.
48. Eleff SM, Barker PB, Blackband SJ, et al. Phosphorus magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine [see comments]. Ann Neurol 1990;27:626-630.
49. Gideon P, Henriksen O, Sperling B, et al. Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke: a proton magnetic resonance spectroscopy study. Stroke 1992; 23:1566-1572.
50. Kato T, Takahashi S, Shioiri T, et al. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1994;31:125-133.
51. Obrenovitch TP, Garofalo O, Harris RJ, et al. Brain tissue concentrations of ATP, phosphocreatine, lactate, and tissue pH in relation to reduced cerebral blood flow following experimental acute middle cerebral artery occlusion. J Cereb Blood Flow Metab 1988;8:866-874.
52. Bogdanis GC, Nevill ME, Boobis LH, Lakomy HK. Contribution of phosphocreatine and aerobic metabolism to energy supply during repeated sprint exercise. J Appl Physiol 1996; 80:876-884.
53. Bogdanis GC, Nevill ME, Boobis LH, et al. Recovery of power output and muscle metabolites following 30 s of maximal sprint cycling in man. J Physiol (Lond) 1995;482:467-480.
54. Sahlin K, Harris RC, Hultman E. Resynthesis of creatine phosphate in human muscle after exercise in relation to intramuscular pH and availability of oxygen. Scand J Clin Lab Invest 1979;39:551-558.
55. Radda GK, Taylor DJ, Arnold DL. Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Biochem Soc Trans 1985;13:654.
56. Westerblad H, Lannergren J. Reduced maximum shortening velocity in the absence of phosphocreatine observed in intact fibres of Xenopus skeletal muscle. J Physiol (Lond) 1995;482: 383-390.
57. Kaldis P, Hemmer W, Zanolla E, et al. "Hot spots" of creatine kinase localization in brain: cerebellum, hippocampus and choroid plexus. Dev Neurosci 1996;18:542-554.
58. Brdiczka D, Wallimann T. The importance of the outer mitochondrial compartment in regulation of energy metabolism. Mol Cell Biochem 1994;133-134:69-83.
59. Rojo M, Hovius R, Demel RA, et al. Mitochondrial creatine kinase mediates contact formation between mitochondrial membranes. J Biol Chem 1991;266:20290-20295.
60. Brdiczka D, Beutner G, Ruck A, et al. The molecular structure of mitochondrial contact sites: their role in regulation of energy metabolism and permeability transition. Biofactors 1998;8:235-242.
61. Stachowiak O, Dolder M, Wallimann T, Richter C. Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation. J Biol Chem 1998; 273:16694-16699.
62. O'Gorman E, Beutner G, Dolder M, et al. The role of creatine kinase inhibition of mitochondrial permeability transition. FEBS Lett 1997;414:253-257.
63. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprocective effects of creatine in a transgenic animal model of ALS. Nat Med 1998;5:347-350.
64. Koufen P, Ruck A, Brdiczka D, et al. Free radical-induced inactivation of creatine kinase: influence on the octameric and dimeric states of the mitochondrial enzyme (Mib-CK). Biochem J 1999;344:413-417.
65. Xu CJ, Klunk WE, Kanfer JN, et al. Phosphocreatine-dependent glutamate uptake by synaptic vesicles. J Biol Chem 1996;271:13435-13440.
66. O'Gorman E, Fuchs KH, Tittmann P, et al. Crystalline mitochondrial inclusion bodies isolated from creatine depleted rat soleus muscle. J Cell Sci 1997;110:1403-1411.
67. Tarnopolsky MA, Chorneyko K, Simon D, Johns D. Reversal of paracrystalline inclusions in a patient with a G15497A missense mutation following creatine monohydrate supplementation. In: Zullo SJ, ed. Mitochondrial Interest Group Minisymposium (Mitochondria: Interaction of Two Genomes). Bethesda, MD: NIH; 2000. p. 27.
68. Ingwall JS. Creatine and the control of muscle-specific protein synthesis in cardiac and skeletal muscle. Circ Res 1976;38: 1115-1123.
69. Ingwall JS, Weiner CD, Morales MF, et al. Specificity of creatine in the control of muscle protein synthesis. J Cell Biol 1974;62:145-151.
70. Earnest CP, Snell PG, Rodriguez R, et al. The effect of creatine monohydrate ingestion on anaerobic power indices, muscular strength and body composition. Acta Physiol Scand 1995;153:207-209.
71. Mihic S, MacDonald JR, McKenzie S, Tarnopolsky MA. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Med Sci Sports Exerc 2000;32:291-296.
72. Dangott B, Schultz E, Mozdziak PE. Dietary creatine monohydrate supplementation increases satellite cell mitotic activity during compensatory hypertrophy. Int J Sports Med 2000;21: 13-16.
73. Wallimann T, Wyss M, Brdiczka D, et al. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the "phosphocreatine circuit" for cellular energy homeostasis. Biochem J 1992;281:21-40.
74. van Leemputte M, Vandenberghe K, Hespel P. Shortening of muscle relaxation time after creatine loading. J Appl Physiol 1999;86:840-844.
75. Harris RC, Soderlund K , Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci 1992;83:367-374.
76. Hultman E, Soderlund K, Timmons JA, et al. Muscle creatine loading men. J Appl Physiol 1996;81:232-237.
77. Dechent P, Pouwels PJ, Wilken B, et al. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol 1999;277:R698-R704.
78. Tarnopolsky MA, Parshad A, Walzel B, et al. Creatine transporter (CreaT) and mitochondrial creatine kinase protein content in myopathies: significant reduction of CreaT in myopathies. Muscle Nerve (in press).
79. Gordon A, Hultman E, Kijser L, et al. Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res 1995;30: 413-418.
80. Greenhaff PL, Casey A, Short AH, et al. Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin Sci (Colch) 1993;84:565-571.
81. Kamber M, Koster M, Kreis R, et al. Creatine supplementation - part 1: performance, clinical chemistry, and muscle volume. Med Sci Sports Exerc 1999;31:1763-1769.
82. Kreider RB, Ferreira M, Wilson M, et al. Effects of creatine supplementation on body composition, strength, and sprint performance. Med Sci Sports Exerc 1998;30:73-82.
83. Vandenberghe K, Goris M, Van Hecke P, et al. Long-term creatine intake is beneficial to muscle performance during resistance training. J Appl Physiol 1997;83:2055-2063.
84. Volek JS, Kraemer WJ, Bush JA, et al. Creatine supplementation enhances muscular performance during high-intensity resistance exercise. J Am Diet Assoc 1997;97:765-770.
85. Volek JS, Duncan ND, Mazzetti SA, et al. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. Med Sci Sports Exerc 1999;31: 1147-1156.
86. Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol 1994;266:E725-E730.
87. Vandenberghe K, Van Hecke P, Van Leemputte M, et al. Phosphocreatine resynthesis is not affected by creatine loading. Med Sci Sports Exerc 1999;31:236-242.
88. Sipila I, Rapola J, Simell O, Vannas A. Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. N Engl J Med 1981;304:867-870.
89. Koshy KM, Griswold E, Schneeberger EE. Interstitial nephritis in a patient taking creatine [letter]. N Engl J Med 1999; 340:814-815.
90. Pritchard NR, Kalra PA. Renal dysfunction accompanying oral creatine supplements. Lancet 1998;351:1252-1253.
91. Poortmans JR, Auquier H, Renaut V, et al. Effect of short-term creatine supplementation on renal responses in men. Eur J Appl Physiol 1997;76:566-567.
92. Poortmans JR, Francaux M. Long-term oral creatine supplementation does not impair renal function in healthy athletes. Med Sci Sports Exerc 1999;31:1108-1110.
93. Vahedi K, Domigo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. J Neurol Neurosurg Psychiatry 2000;68:112-113.
94. Lee MK, Cheng BW, Che CT, Hsieh DP. Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. Toxicol Sci 2000;56:424-430.
95. Terjung RL, Clarkson P, Eichner ER, et al. American College of Sports Medicine roundtable: the physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc 2000;32:706-717.
96. Febbraio MA, Flanagan TR, Snow RJ, et al. Effect of creatine supplementation on intramuscular TCr, metabolism and performance during intermittent, supramaximal exercise in humans. Acta Physiol Scand 1995;155:387-395.
97. Wilken B, Ramirez JM, Probst I, et al. Anoxic ATP depletion in neonatal mice brainstem is prevented by creatine supplementation. Arch Dis Child Fetal Neonatal Ed 2000;82:F224-F227.
98. Carter AJ, Muller RE, Pschorn U, Stransky W. Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices. J Neurochem 1995;64:2691-2699.
99. Whittingham TS, Lipton P. Cerebral synaptic transmission during anoxia is protected by creatine. J Neurochem 1981;37: 1618-1621.
100. Malcon C, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res 2000;860:195-198.
101. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
102. Tabrizi SJ, Workman J, Hart PE, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 2000;47:80-86.
103. Stockler S, Holzbach U, Hanefeld F, et al. Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr Res 1994;36:409-413.
104. Bianchi MC, Tosetti M, Fornai F, et al. Reversible brain creatine deficiency in two sisters with normal blood creatine level. Ann Neurol 2000;47:511-513.
105. Sipila I. Inhibition of arginine-glycine amidinotransferase by ornithine: a possible mechanism for the muscular and chorioretinal atrophies in gyrate atrophy of the choroid and retina with hyperornithinemia. Biochim Biophys Acta 1980;613:79-84.
106. Vannas-Sulonen K, Sipila I, Vannas A, et al. Gyrate atrophy of the choroid and retina: a five-year follow-up of creatine supplementation. Ophthalmology 1985;92:1719-1727.
107. Nanto-Salonen K, Komu M, Lundbom N, et al. Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia [see comments]. Neurology 1999;53:303-307.
108. Heinanen K, Nanto-Salonen K, Komu M, et al. Creatine corrects muscle 31P spectrum in gyrate atrophy with hyperornithinaemia. Eur J Clin Invest 1999;29:1060-1065.
109. Borchert A, Wilichowski E , Hanefeld F. Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies. Muscle Nerve 1999;22:1299-1300.
110. Hagenfeldt L, von Dobeln U, Solders G , Kaijser L. Creatine treatment in MELAS. Muscle Nerve 1994;17:Oct:1236-1237.
111. Meyers AR, Gage H, Hendricks A. Health-related quality of life in neurology. Arch Neurol 2000;57:1224-1227.
112. Beyer RE. An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol 1992;70:390-403.
113. Do TQ, Schultz JR, Clarke CF. Enhanced sensitivity of ubiquinone-deficient mutants of saccharomyces cerevisiae to products of autoxidized polyunsaturared fatty acids. Proc Natl Acad Sci USA 1996;93:7534-7539.
114. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271:195-204.
115. Forsmark-Andree P, Lee C-P, Dallner G, Ernster L. Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radie Biol Med 1997;22:391-400.
116. Noack H, Kube U, Augustin W. Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic Res 1994;20:375-386.
117. Kagan T, Davis C, Lin L, Zakeri Z. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann NY Acad Sci 1999;887:31-47.
118. Abe K, Fujimura H, Nishikawa Y, et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 1991; 83:356-359.
119. 10. Neurology 1988;38:892-899.
120. 10 and idebenone. J Neurol Sci 1989; 90:263-271.
121. 31P NMR study. Neurology 1989;39:399-403.
122. Tomasetti M, Littarru GP, Stocker R, Alleva R. Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Radic Biol Med 1999;27:1027-1032.
123. Abe K, Matsuo Y, Kadekawa J, et al. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. J Neurol Sci 1999;162:65-68.
124. Chan A, Reichmann H, Kogel A, et al. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998;245:681-685.
125. Chariot P, Brugieres P, Eliezer-Vanerot MC, et al. Choreic movements and MRI abnormalities in the subthalamic nuclei reversible after administration of coenzyme Q10 and multiple vitamins in a patient with bilateral optic neuropathy. Mov Disord 1999;14:855-859.
126. Matthews PM, Ford B, Dandurand RJ, et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43:884-890.
127. Matthews RT, Yang L, Browne S, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 1998; 95:8892-8897.
128. Turunen M, Appelkvist EL, Sindelar P, Dallner G. Blood concentration of coenzyme Q(10) increases in rats when esterified forms are administered. J Nutr 1999;129:2113-2118.
129. Zhang Y, Aberg F, Appelkvist EL, et al. Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr 1995;125: 446-453.
130. Lass A, Forster MJ, Sohal RS. Effects of coenzyme Q10 and a-tocopherol administration on their tissue levels in the mouse: elevation of mitochondrial alpha-tocopherol by coenzyme Q10. Free Radic Biol Med 1999;26:1375-1382.
131. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994;36:882-888.
132. 10 attenuates the MPTP induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1997;783: 109-114.
133. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999;354:477-479.
134. Cortelli P, Montagna P, Pierangeli G, et al. Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study. J Neurol Sci 1997;148:25-31.
135. Sram RJ, Binkova B, Stejskalova J, Topinka J, Effect of EGb 761 on lipid peroxidation, DNA repair and antioxienzyme activity. In: Ferradini C, Droy-Lefaix MT, Christen Y, eds. Advances in Ginkgo biloba extract research, vol. 2: Ginkgo biloba extract (EGb 761) as a free-radical scavenger. Paris: Elsevier; 1993. p 27-38.
136. Kobuchi H, Droy-Lefaix MT, Christen Y, Packer L. Ginkgo biloba extract (EGb 761): inhibitory effect on nitric oxide production in the macrophage cell line RAW 264.7. Biochem Pharmacol 1997;53:897-903.
137. Oyama Y, Chikahisa L, Ueha T, et al. Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain Res 1996;712:349-352.
138. Du G, Willer K, Mouithys-Mickalad A, et al. EGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxygenation. Free Radic Biol Med 1999;27:596-604.
139. Sastre J, Millan A, Garcia de la Asuncion J, et al. A Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic Biol Med 1998; 24:298-304.
140. Ramassamy C, Clostre F, Christen Y, Costentin J. In vivo Ginkgo biloba extract (EGh 761) protects against neurotoxic effects induced by MPTP: investigations into its mechanism(s) of action. In: Christen Y, Costentin J, Lacour M, eds. Effects of Gingko biloba extract (EGb 761) on the central nervous system. Paris: Elsevier; 1992. p 27-36.
141. Ferrante RJ, Beal MF. Neuroprotective effects of Gingko biloba extract in ALS transgenic mice. In: Christen Y, ed. Effects of Gingko biloba extract on the central nervous system. Paris: Elsevier (in press).
142. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia: North American EGb Study Group. JAMA 1997;278:1327-1332.
143. Oken BS, Storzbach DM, Kaye JA. The efficacy of Gingko biloba on cognitive function in Alzheimer's disease. Arch Neurol 1998;55:1409-1415.
144. Eliasson MJL, Sampei K, Mandir AS, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistent to cerebral ischemia. Nat Med 1997;3:1089-1095.
145. Mandir AS, Przedborski S, Jackson-Lewis V, et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci USA 1999;96:5774-5779.
146. Ayoub IA, Lee EJ, Ogilvy CS, et al. Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. Neurosci Lett 1999;259:21-24.
147. Cosi C, Marien M. Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res 1998;809:58-67.
148. 10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol 1995;132:279-283.
149. Majamaa K, Rusanen H, Remes AM, et al. Increase of blood NAD+ and attenuation of lactacidemia during nicotinamide treatment of a patient with the MELAS syndrome. Life Sci 1996;58:691-699.
150. 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42:2147-2152.
151. Bernsen PLJA, Gabreels FJM, Ruitenbeek W, Hamburger HL. Treatment of complex I deficiency with riboflavin. J Neurol Sci 1993;118:181-187.
152. Ogle RF, Christodoulou J, Fagan E, et al. Mitochondrial myopathy with tRNA(Leu(UUR)) mutation and complex I deficiency responsive to riboflavin. J Pediatr 1997;130:138-145.
153. Scholte HR, Busch HF, Bakker HD, et al. Riboflavin-responsive complex I deficiency. Biochim Biophys Acta 1995; 1271:75-83.
154. Antozzi C, Garavaglia B, Mora M, et al. Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme A dehydrogenase and respiratory chain deficiency. Neurology 1994;44:2153-2158.
155. Peluchetti D, Antozzi C, Roi S, et al. Riboflavin responsive multiple acyl-CoA dehydrogenase deficiency: functional evaluation of recovery after high dose vitamin supplementation. J Neurol Sci 1991;105:93-98.
156. Vergani L, Barile M, Angelini C, et al. Riboflavin therapy. Biochemical heterogeneity in two adult lipid storage myopathies. Brain 1999;122:2401-2411.
157. Di Lisa F, Bobyleva-Guarriero V, Jocelyn P, et al. Stabilising action of carnitine on energy linked processes in rat liver mitochondria. Biochem Biophys Res Commun 1985;131:968-973.
158. Hagen TM, Ingersoll RT, Wehr CM, et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA 1998;95:9562-9566.
159. 1H NMR spectroscopy. Brain Res 1990;526:108-112.
160. Virmani MA, Biselli R, Spadoni A, et al. Protective actions of L-carnitine and aceryl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol Res 1995;32:383-389.
161. Snyder JW, Kyle ME, Ferraro TN. L-carnitine delays the killing of cultured hepatocytes by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Arch Biochem Biophys 1990;276:132-138.
162. Matsuoka M, Igisu H. Preservation of energy metabolites by carnitine in the mouse brain under ischemia. Brain Res 1992; 590:334-336.
163. 1H-NMR spectroscopy. Brain Res 1994;643:9299.
164. Rosenthal RE, Chanderbhan R, Marshall G , Fiskum G. Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxylethyl starch-conjugated deferoxamine. Free Radic Biol Med 1992;12:29-33.
165. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991; 41:1726-1732.
166. 1-antiproteinase inactivation by oxidized and reduced lipoic acid. FEBS Lett 1996;379:74-76.
167. Wolz P, Krieglstein J. Neuroprotective effects of alpha-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharmacology 1996;35:369-375.
168. Panigrahi M, Sadguna Y, Shivakumar BR, et al. a-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res 1996;717:184-188.
169. Lykkesfeldt J, Hagen TM, Vinarsky V, Ames BN. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes - reversal with (R)-alpha-lipoic acid supplementation. FASEB J 1998;12:1183-1189.
170. Hagen TM, Ingersoll RT, Lykkesfeldt J, et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 1999;13:411-418.
171. Marangon K, Devaraj S, Tirosh O, et al. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. Free Radic Biol Med 1999;27:1114-1121.
172. Barbiroli B, Medori R, Tritschler HJ, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J Neurol 1995;242:472-477.
173. Haak E, Usadel KH, Kusterer K, et al. Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes 2000;108:168-174.
174. Androne L, Gavan NA, Veresiu IA, Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000;14:327-330.
175. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II): Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999;31:171-179.
176. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabetes Med 1999;16:1040-1043.
177. Morten KJ, Caky M, Matthews PM. Stabilization of the pyruvate dehydrogenase E1a subunit by dichloroacetate. Neurology 1998;51:1331-1335.
178. Chang LH, Shimizu H, Abiko H, et al. Effect of dichloroacetate on recovery of brain lactate, phosphorus energy metabolites, and glutamate during reperfusion after complete cerebral ischemia in rats. J Cereb Blood Flow Metab 1992;12:1030-1038.
179. Katayama Y, Welsh FA. Effect of dichloroacetate on regional energy metabolites and pyruvate dehydrogenase activity during ischemia and reperfusion in gerbil brain. J Neurochem 1989; 52:1817-1822.
180. Peeling J, Sutherland G, Brown RA, Curry S. Protective effect of dichloroacetate in a rat model of forebrain ischemia. Neurosci Lett 1996;208:21-24.
181. McVeigh JJ , Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 1990;259:H1079-H1085.
182. Stacpoole PW, Barnes CL, Hurbanis MD, et al. Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 1997;77:535-541.
183. De Stefano N, Matthews PM, Ford B, et al. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995;45:1193-1198.
184. Harada M, Tanouchi M, Arai K, et al. Therapeutic efficacy of a case of pyruvate dehydrogenase complex deficiency monitored by localized proton magnetic resonance spectroscopy. Magn Reson Imaging 1996;14:129-133.
185. Pavlakis SG, Kingsley PB, Kaplan GP, et al. Magnetic resonance spectroscopy. Arch Neurol 1998;55:849-852.
186. Taivassalo T, Matthews PM, De Stefano N, et al. Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency. Neurology 1996;47:529-534.
187. Takanashi J, Sugita K, Tanabe Y, et al. Dichloroacetate treatment in Leigh syndrome caused by mitochondrial DNA mutation. J Neurol Sci 1997;145:83-86.
188. Kimura S, Osaka H, Saitou K, et al. Improvement of lesions shown on MRI and CT scan by administration of dichloroacetate in patients with Leigh syndrome. J Neurol Sci 1995; 134:103-107.
189. Saitoh S, Momoi MY, Yamagata T, et al. Effects of dichloroacetate in three patients with MELAS. Neurology 1998;50: 531-534.
190. Graham GD, Barker PB, Brooks WM, et al. MR spectroscopy study of dichloroacetate treatment after ischemic stroke. Neurology 2000;55:1376-1378.
191. Haas R, Barshop B, Naviaux R, William N. Results of the UCSD open label dichloroacetrate trial in congenital lactic acidosis. In: Zullo SJ, ed. Mitochondrial Interest Group Mini-symposium (Mitochondria: Interaction of Two Genomes). Bethesda, MD: NIH, 2000. p. 2.
192. Gansted U, Quistorff B, Vissing J. Dichloroacetate treatment of mitochondrial myopathy patients. Neurology 1999; 52(Suppl 2):A544.
193. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1998;1366:211-223.